Draupnir Bio (private company)

See something wrong or missing? Let us know
Offices:
Aarhus
Registration number:
38546880
Business model:
B2B
Investors:
we tracked 3 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 1 transaction

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Draupnir Bio was set out to develop a new type of cholesterol-lowering medicine and developed a platform for exploring the glycome to develop novel therapeutics. The platform is based on array technology, protein chemistry and advanced carbohydrate chemistry.

Companies with similar profile to Draupnir Bio:

CompanyCriteria
Denmark Galecto Biotech
66%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Denmark AFYX Therapeutics
66%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Denmark NMD Pharma
66%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds, INKEF Capital
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Denmark MinervaX
56%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
Finland Synoste Oy
55%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: High-Tech Gründerfonds
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden AMRA
55%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Finland Forendo Pharma
55%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Finland Mobidiag
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Denmark STipe Therapeutics
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden ITBMed
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Aprea Therapeutics
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Iceland Alvotech
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Norway Oncoinvent
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Denmark Unibio
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 10M+ USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Merozyne Therapeutics
46%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Denmark Antag Therapeutics
46%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
Denmark BioPhero
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Minim one investor from outside Scandinavia: Yes
Denmark Acesion Pharma
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Minim one investor from outside Scandinavia: Yes
Denmark Biosyntia
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Novo Seeds
  • Minim one investor from outside Scandinavia: Yes
Finland Optomed
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes